Racura Oncology Ltd (ASX: RAC) - Share Price

Current share price for RAC : $2.050 0.05 (2.38%)⁺

Racura Oncology (RAC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Phase 3 clinical biopharmaceutical company with a mission to be at the heart of cancer care.

RAC General Information ⁺

ASX Code	RAC
Website	http://www.racuraoncology.com
Industry/Sector	Biotechnology
Market Cap ($M)	401
RAC Share Price	$2.050
Day High	$2.090
Day Low	$2.030
Last Close	$2.100
RAC Share Price Movement	$0.05 ( 2.38% )

Prices as at 16:40, 12 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Racura Oncology Ltd (RAC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Racura Oncology Ltd (RAC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Racura Oncology Ltd (RAC) price-sensitive announcements

RAC - First HARNESS-1 Patient Safely Treated with RC220

Racura Oncology Ltd has announced the successful treatment of the first patient in its HAR

Racura Oncology Ltd (RAC)
29 Jul 2026 | 9:04 AM

RAC - June 2026 Quarterly Activities Report and Appendix 4C

Racura Oncology Ltd reported significant clinical and corporate advancements in its June 2

Racura Oncology Ltd (RAC)
28 Jul 2026 | 9:12 AM

RAC - Bellberry Ethics Approval Activates New HARNESS Trial Sites

Racura Oncology Ltd announced the Bellberry Human Research Ethics Committee (HREC) approva

Racura Oncology Ltd (RAC)
3 Jul 2026 | 8:46 AM

RAC - Racura Treats First Patient in HARNESS-1 Lung Cancer Trial

Racura Oncology Ltd has announced the treatment of the first patient in the HARNESS-1 Phas

Racura Oncology Ltd (RAC)
25 Jun 2026 | 8:55 AM

Racura Oncology Ltd (RAC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	Racure Oncology Techknow Invest Presentation	29 Jul 2026 9:12AM	$2.040	$2.050	risen by 0.49%
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	First HARNESS-1 Patient Safely Treated with RC220	29 Jul 2026 9:04AM	$2.040	$2.050	risen by 0.49%
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	June 2026 Quarterly Activities Report and Appendix 4C	28 Jul 2026 9:12AM	$2.070	$2.050	fallen by 0.97%
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	Notification of cessation of securities - RAC	13 Jul 2026 8:57AM	$2.190	$2.050	fallen by 6.39%
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	Racura to Present CPACS Data at GCOS 2026	9 Jul 2026 10:42AM	$2.130	$2.050	fallen by 3.76%
Racura Oncology Ltd (RAC) ORDINARY FULLY PAID	Health Care	$402	Racura Oncology New Zealand Investor Events	6 Jul 2026 12:38PM	$2.250	$2.050	fallen by 8.89%

RAC Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$4.79	-$2.80	-66.90%	0.00%	0.0%
2024A	-$13.82	-$8.40	36.10%	0.00%	0.0%
2023A	-$9.92	-$6.20	-15.60%	0.00%	0.0%

RAC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$66,248M	0.1108	-0.1236	0.0167	14.8332	16.9242	16.6464	3.22%	2.62%	2.73%
Clinuvel Pharmaceuticals Limited (CUV)	$490M	0.0287	0.0000	0.0000	13.5237	0.0000	0.0000	0.51%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,130M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Racura Oncology Ltd (RAC)	$412M	-0.6690	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,759M	-1.3893	0.0000	-0.1450	0.0000	279.2422	326.5896	0.00%	0.00%	0.00%

RAC Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	22.20	0.00
Market	0.31	13.10	1.15	0.66
Sector	0.52	33.10	2.46	2.71

RAC Directors

Name	Position	Start Date
Dr Daniel Tillett	Chief Executive Officer, Managing Director	1 Sep 2024
Dr Peter (Pete) Smith	Executive Director, Executive Chairman	28 Jun 2023
Dr Megan Baldwin	Non-Executive Director	1 Jan 2025
Dr Serge Scrofani	Non-Executive Director	1 Sep 2024

Racura Oncology Ltd (RAC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
5 Jun 2026	SCROFANI, Serge	Buy	Indirect Shares	11,285	$2.692	$30,375.290
28 May 2026	TILLETT, Daniel	Exercise	Options	400,000	$1.250	$500,000.000
28 May 2026	TILLETT, Daniel	Buy	Direct Shares	400,000	$1.250	$500,000.000

See all changes in directors' interest & trades for Racura Oncology Ltd (RAC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAC Management

Name	Position
Peter Webse	Company Secretary

RAC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Racura Oncology Ltd (RAC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
17,267,615 (9.94%)	Daniel Tillett

RAC Calendar of Events

Date	Event
26 February 2027	Report (Interim)
25 August 2026	Report (Annual)
25 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us